UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies

Human vaccines & immunotherapeutics, 2022-11, Vol.18 (6), p.2132798-2132798

2022

Volltextzugriff (PDF)

A local reaction at or near injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data

Vaccine, 2008-12, Vol.26 (52), p.6800-6813

2008

Volltextzugriff (PDF)

On the bias in HI titers and how to reduce it

Vaccine, 2006-11, Vol.24 (44), p.6645-6646

2006

Volltextzugriff (PDF)

The European CHMP criteria for influenza vaccine immunogenicity cannot be improved by the use of confidence intervals

Vaccine, 2006-11, Vol.24 (44), p.6643-6644

2006

Volltextzugriff (PDF)

Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies

Archives of internal medicine (1960), 1999-01, Vol.159 (2), p.182

1999

Volltextzugriff (PDF)

Annually repeated influenza vaccination improves humoral responses to several influenza virus strains in healthy elderly

Vaccine, 1997-08, Vol.15 (12), p.1323-1329

1997

Volltextzugriff (PDF)

Neural processing of observed performance-based errors and rewards in the context of friends and unfamiliar peers across adolescence

Neuropsychologia, 2023-09, Vol.188, p.108619-108619, Article 108619

2023

Volltextzugriff (PDF)

Longitudinal effects of rTMS on neuroplasticity in chronic treatment-resistant depression

European archives of psychiatry and clinical neuroscience, 2021-02, Vol.271 (1), p.39-47

2021

Volltextzugriff (PDF)

CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer

Nature communications, 2023-01, Vol.14 (1), p.183-21, Article 183

2023

Volltextzugriff (PDF)

Antibody-mediated NK cell activation as a correlate of immunity against influenza infection

Nature communications, 2023-08, Vol.14 (1), p.5170-5170, Article 5170

2023

Volltextzugriff (PDF)

High‐Dose Quadrivalent Influenza Vaccine for Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults

Influenza and other respiratory viruses, 2024-04, Vol.18 (4), p.e13270-n/a

2024

Volltextzugriff (PDF)

Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: Rationale and design of a real-world pragmatic randomized clinical trial

The American heart journal, 2021-07, Vol.237, p.54-61

2021

Volltextzugriff (PDF)

Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial

Vaccine, 2023-04, Vol.41 (15), p.2553-2561

2023

Volltextzugriff (PDF)

Quadrivalent inactivated influenza vaccine (VaxigripTetra™)

Expert review of vaccines, 2018-01, Vol.17 (1), p.1-11

2018

Volltextzugriff (PDF)

Corrigendum to “Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35 months: Analysis of data from a phase III trial in the northern and southern Hemispheres” [Vaccine 37(13) (2019) 1885–1888]

Vaccine, 2023-01, Vol.41 (2), p.621-621

2023

Volltextzugriff (PDF)

Research in Action—Students’ Perspectives on the Integration of Research Activities in Undergraduate Biomedical Curricula

Medical science educator, 2021-04, Vol.31 (2), p.371-374

2021

Volltextzugriff (PDF)

Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research

Sarcoma, 2021, Vol.2021, p.1-12

2021

Volltextzugriff (PDF)

Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial

Vaccine, 2019-09, Vol.37 (39), p.5825-5834

2019

Volltextzugriff (PDF)

Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35 months: Analysis of data from a phase III trial in the Northern and Southern Hemispheres

Vaccine, 2019-03, Vol.37 (13), p.1885-1888

2019

Volltextzugriff (PDF)

Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial

Human vaccines & immunotherapeutics, 2020-06, Vol.16 (6), p.1380-1384

2020

Volltextzugriff (PDF)

Conversion of a colorectal cancer guideline into clinical decision trees with assessment of validity

International journal for quality in health care, 2021-04, Vol.33 (2)

2021

Volltextzugriff (PDF)

Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly

Vaccine, 2007-12, Vol.26 (1), p.119-127

2007

Volltextzugriff (PDF)

160. Safety and Immunogenicity of Escalating Dose Formulations of High-dose Quadrivalent Influenza Vaccine in Children 6 Months Through < 18 Years of Age

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S209-S210

2020

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(28)

Publikationsform

Sprache

Englisch
(30)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Life Sciences & Biomedicine
(24)
Immunology
(16)
Humans
(15)
Influenza
(12)
Medicine, Research & Experimental
(11)
Research & Experimental Medicine
(11)
Vaccines
(11)
Aged
(8)
Biological And Medical Sciences
(8)
Immunization
(8)
Influenza, Human - Prevention & Control
(8)
Safety
(8)
Female
(7)
Immunogenicity
(7)
Influenza Vaccines - Immunology
(7)
Microbiology
(7)
Fundamental And Applied Biological Sciences. Psychology
(6)
Male
(6)
Middle Aged
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies

A local reaction at or near injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data

On the bias in HI titers and how to reduce it

The European CHMP criteria for influenza vaccine immunogenicity cannot be improved by the use of confidence intervals

Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies

Annually repeated influenza vaccination improves humoral responses to several influenza virus strains in healthy elderly

Neural processing of observed performance-based errors and rewards in the context of friends and unfamiliar peers across adolescence

Longitudinal effects of rTMS on neuroplasticity in chronic treatment-resistant depression

CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer

Antibody-mediated NK cell activation as a correlate of immunity against influenza infection

High‐Dose Quadrivalent Influenza Vaccine for Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults

Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: Rationale and design of a real-world pragmatic randomized clinical trial

Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial

Quadrivalent inactivated influenza vaccine (VaxigripTetra™)

Corrigendum to “Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35 months: Analysis of data from a phase III trial in the northern and southern Hemispheres” [Vaccine 37(13) (2019) 1885–1888]

Research in Action—Students’ Perspectives on the Integration of Research Activities in Undergraduate Biomedical Curricula

Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research

Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial

Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6–35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres

The Dutch Transplantation in Vasculitis (DUTRAVAS) Study: Outcome of Renal Transplantation in Antineutrophil Cytoplasmic Antibody-associated Glomerulonephritis

Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35 months: Analysis of data from a phase III trial in the Northern and Southern Hemispheres

Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial

Conversion of a colorectal cancer guideline into clinical decision trees with assessment of validity

Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly

160. Safety and Immunogenicity of Escalating Dose Formulations of High-dose Quadrivalent Influenza Vaccine in Children 6 Months Through < 18 Years of Age

Suchergebnisse filtern